In congruency with these efforts, the Food and Drug Administration (FDA) has approved several biomarker-based precision medicines, including Trastuzumab, which is indicated for breast cancer patients demonstrating human epidermal growth factor receptor 2 (HER2) gene amplification with subsequent elevations in protein level [2,3]. This evidence concerns the gene ERBB2 and breast carcinoma.